Table: Taisho Pharmaceutical HD -Q1 group results
Aug 5 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2021 Jun 30, 2020 Mar 31, 2022
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 63.88 75.02 269.00
(-14.8 pct) (+24.5 pct) (-4.6 pct)
Operating 2.68 9.39 14.50
(-71.5 pct) (+12.8 pct) (-27.4 pct)
Recurring 4.03 11.12 18.50
(-63.7 pct) (+45.3 pct) (-28.7 pct)
Net 1.18 6.06 10.50
(-80.5 pct) (-44.9 pct) (-21.1 pct)
EPS 14.78 yen 75.98 yen 131.45 yen
EPS Diluted 14.75 yen 75.89 yen
Ann Div 100.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10